Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)

ClinicalTrials.gov ID: NCT00761098

Public ClinicalTrials.gov record NCT00761098. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Spontaneous bacterial peritonitis (SBP) is a common and frequently fatal complication of end-stage liver disease with a mortality of up to 10%, primarily due to the development of kidney failure. Current standard practice is to treat this infection with broad spectrum antibiotics and salt-poor albumin administration on day one and three of treatment. In this study the investigators test the hypothesis that the administration of a second dose of albumin at 48 hours only to patients with renal insufficiency, is as effective at preventing kidney failure as administering the second dose to all patients at 72 hours.

Study identification

NCT ID: NCT00761098
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Weill Medical College of Cornell University; Other
Enrollment: 80 participants

Conditions and interventions

Conditions

Interventions

Standard Care Drug
Experimental Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 30, 2005
Primary completion: Apr 30, 2010
Completion: Jul 31, 2010
Last update posted: Jan 3, 2011

2005 – 2010

United States locations

U.S. sites: 2
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
New York Presbyterian Hospital - Weill Cornell Medical Center	New York	New York	10021	Recruiting
New York Presbyterian Hospital - Columbia University Medical Center	New York	New York	10032	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00761098, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 3, 2011 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00761098 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →